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Abstract
MicroRNA (miRs) represent a class of small non-coding regulatory RNAs playing a major role in the control of gene
expression by repressing protein synthesis at the post-transcriptional level. Studies carried out during the last years
have shown that some miRNAs plays a key role in the control of normal and malignant hgematopoiesis. In this
review we focus on recent progress in analyzing the functional role of miR-146a in the control of normal and
malignant hematopoiesis. On the other hand, this miRNA has shown to impact in the control of innate immune
responses. Finally, many recent studies indicate a deregulation of miR-146 in many solid tumors and gene
knockout studies indicate a role for this miRNA as a tumor suppressor.
MiR-146a: discovery and targets
Most vertebrates have two copies of the gene encoding
miR-146, miR-146a and miR-146b, located at the level
of different chromosomes, 5 and 10, respectively, within
different genes. The structural differences of these two
miRNAs are very limited since they differ in their
mature sequences by just two nucleotides located at the
3’ end. In spite these great structural similarities, miR-
146a and miR-146b do not seem to be redundant in
their biologic activity, as suggested by the observation
that they may have a different post-transcritpional pro-
cessing mechanism: thus, following lipopolysaccharide
stimulation the transcription of both miR-146a and
miR-146b is stimulated, but only mature miR-146a is
produced [1].
MiR-146a was initially discovered during a systematic
study aiming to identify miRNAs that play a potentially
important role in the innate immune response to micro-
bial infection [2]. Particularly, expression profiling of
200 miRNAs in human monocytes revealed that some
miRNAs, including miR-146a and miR-155, are strongly
upmodulated following challenging of these cells with
bacterial endotoxin [2]. The analysis of the miR-146a
promoter provided evidence that miR-146a is a NF-kap-
paB-dependent gene [2]. miR-146a was predicted to
base-pair with sequences in the 3’ UTR of the TNF
receptor-associated factor 6 (TRAF6) and IL-1 receptor-
associated kinase 1 (IRAK1) genes (Table 1). Both these
two genes encode key adaptor molecules downstream of
Toll-like and cytokine receptors.
Studies carried out in vesicular stomatitis virus (VSV)-
infected macrophages showed that macrophage infarc-
tion induced a marked upmodulation of miR-146a that
was shown to target IRAK2, in addition to the pre-
viously reported TRAF6 and IRAK1 [3].
The study of human lung alveolar epithelial cells have
led to the identification of additional miR-146a targets
involved in the control of innate immunity. In fact,
Perry and coworkers showed that exposure of human
lung alveolar epithelial cells to IL-1b resulted in a very
pronounced increase of miR-146a levels, that in turn
induced a decrease of IL-8 and RANTES chemokines
through targeting of the 3’ UTRs of their respective
mRNAs [4].
Based on experiments carried out on HIV-infected
microglial cells, Rom et al have shown that miR-146a
targets in these cells the 3’ UTR of the CCL8 (MCP2)
mRNA, leading to a decreased release of this chemokine
[5]. According to these observations it was suggested
that miR-146a may act as a modulator in macrophages/
microglial cells of the production of the pro-inflamma-
tory cytokine CCL8 (MCP2).
A recent study provided evidence that miR-146a, in
addition to act as a modulator of the innate immune
response, plays also a role as a modulator of the adap-
tive immune response. Thus, it was shown that miR-
146a is scarcely expressed in naïve T cells, while is
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abundantly expressed in human memory T cells [6].
miR-146a expression is clearly induced following T cell
activation via T cell receptor stimulation. During T cell
activation miR-146a upmodulation plays an anti-apopto-
tic role, mediated through the targeting of FADD
mRNA [6]. miR-146a modulates also IL-2 production in
activated T lymphocytes [6]. According to all these
observations it was suggested that miR-146a plays also a
role in the modulation of adaptive immunity.
In addition to these targets all involved at various
levels in the mechanisms of innate immunity, miR-146a
targets also other mRNAs encoding for proteins whose
function in more related to the controls of other cellular
activities, such as cell proliferation, differentiation and
migration. Thus, studies carried out on breast cancer
cells have led to identify EGF-R as a possible target of
miR-146a (Table 1). These studies were originated from
initial observations showing that overexpression of miR-
146a in breast cancer cells determines an inhibition of
NF-kB activity with reduction of metastatic potential
[14]. After this initial observation, in a second study it
was shown that the capacity of the Breast Cancer
Metastasis Suppressor 1 (BRMS1) protein was depen-
dent on miR-146a upregulation that in turn reduces the
metastatic potential of breast cancer cells and was asso-
ciated with a downmodulation of the Epidermal growth
Factor Receptor [7]. These findings were confirmed in
pancreatic cancer cells showing that natural compounds,
such as isoflavone, suppress the invasive properties of
these cells through a mechanism which involves miR-
146a upmodulation that in turn leads to a decline of
EGFR expression [8]. Similar observations were recently
reported also in gastric cancer cells, where it was shown
that enforced expression of miR-146a inhibited migra-
tion and invasion of tumor cells and downregulated
EGFR and IRAK1 expression [9]. Importantly, this study
showed also that the miR-146a downmodulates EGFR
expression through a direct mechanism involving target-
ing of the 3’ UTR of the EGFR mRNA [9]. In cardio-
myocytes miR-146a targets ERB4, another member of
the EGFR family; in these cells miR-146a up-regulation
was related to cardiotoxic events [15].
A recent study provided some evidence that miR-146a
overexpression in glioblastomas exerts an anti-tumor
effect, seemingly related to the capacity of this micro-
RNA to target in these cells the 3’ UTR of the
NOTCH1 mRNA [11].
Studies carried out in leukemic cell lines and in nor-
mal megakaryocytes have led to the identification of a
new target of miR-146a, the chemokine receptor
CXCR4 [12] (Table 1). Particularly, the identification of
this target was related to studies on PLZF, where it was
Table 1 Molecular Targets of miR-146a
Target Molecules Cellular System Biological Consequences References
TRAF6, IRAK1 (adaptor molecules downstream of
Toll-like and cytokine receptors)
LPS-stimulated monocytes Innate immunity response Taganov et al,
PNAS, [2]
IRAK2 (adaptor molecules downstream of Toll-like
and cytokine receptors)
VSV-infected macrophages Innate immunity response Hou et al, J
Immunol [3]
IL-8, RANTES Lung Epithelial Alveolar Cells Innate immunity response Perry MM et al, J
Immunol [4]
CCL((MCP2) HIV-infected microglial cells Innate immunity response Rom et al, FASEB J,
[5]




Curtale et al, Blood
[6]
EGF-R Breast, pancreatic and gastric cancer Cell proliferation, survival Hurst et al, Cancer
Res [7]
Li et al, Cancer Res,
[8]
Kogo et al, Clin
Cancer Res, [9]
ROCK1 Prostate cancer cells Cell proliferation, invasion
and metastasis
Lin et al, RNA, [10]
NOTCH1 Glioblastoma Cell proliferation, survival
and differentiation
Mei et al, Mol Cell
Biol, [11]
CXCR4 Leukemic cell lines
Hematopoietic progenitors induced to
megakaryocytic differentiation




Labbaye et al, Nat
Cell Biol, [12]
KLF4 Vascular smooth muscle cells Vascular muscle proliferation Sun et al, EMBO
Rep, [13]
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shown that this transcription factor inhibits miR-146a
expression and in turn up-regulates CXCR4 expression
[12]. Through in vitro assays it was shown that PLZF is
able to interact with the miR-146a promoter, while miR-
146a targets the 3’ UTR of the CXCR4 mRNA, imped-
ing its translation [12]. During normal megakaryocytic
differentiation a functionally regulatory loop was
observed, involving PLZF suppressing miR-146a tran-
scription and thereby activating CXCR4 translation [12].
According to these studies, abnormalities of miR-146a
expression (downregulation) in tumors may have impor-
tant consequences for malignancy through enhanced
CXCR4 expression in these cells. The targeting of
CXCR4 mRNA by miR-146a was confirmed also by
other studies showing that the Kaposi’s sarcoma-asso-
ciated hepesvirus-encoded viral FLICE inhibitor protein
(v-FLIP) mediates CXCR4 suppression through miR-
146a upmodulation [16].
Additional miR-146a targets have been recently identi-
fied. In vascular smooth muscle cells miR-146a targets
the 3’ UTR od Kruppel-like Factor 4 (KLF4): silencing
of miR-146a increases KLF4 expression, while its over-
expression induces an opposite effect [13] (Table 1). In
turn, KLF4 acts as a regulator of miR-146a transcription,
acting as a repressor of miR-146a transcription [13]. The
biological consequences of this modulation of KLF4
exerted by miR-146a consist in a stimulation of vascular
muscle proliferation in vitro and a vascular neointimal
hyperplasia in vivo elicited by miR-146a overexpression.
In prostate cancer cells ROCK1, one of the key kinases
for the activation of the hyaluronan, was found to be
targeted by miR-146a [10]. miR-146a enforced expres-
sion in these cancer cells leads to a marked downmodu-
lation of ROCK1, associated with a reduced
proliferation, migration and invasiveness [10].
Expression and function of miR-146a in immune
cells
Many studies were conveyed to the analysis of the
expression and function of miR-146a in various cell
types of the immune system. The analysis of miR-146a
expression in highly purified subsets of cells of the
immune system showed that miR-146a is among the
few miRs to be differentially expressed between Th1 and
Th2 cells in the mouse, thus suggesting that it could be
involved in fate determination of these cells. Studies in
mice made deficient in miR-146a expression by gene
knockout showed an increase in the number of IFN-
gamma-producing T-cell subset (Treg) [10]. In spite the
increased number of Treg lymphocytes induced by miR-
146a deficiency, their function resulted to be impaired,
with a consequent breakdown of immunological toler-
ance with massive lymphocyte activation and tissue infil-
tration in several organs [17]. In human T lymphocytes,
miR-146a is scarcely expressed in naïve T cells, while it
is abundantly expressed in memory T cells and is
induced upon TCR stimulation [6].
As mentioned above, miR-146a is a typical miRNA
involved in the control fo the inflammatory response of
cells of the innate immune system and, particularly
monocytes/macrophages, to infection. As mentioned in
the previous section, miR-146a was found to be induci-
ble in human monocytes upon stimulation with LPS in
a NF-kB dependent manner and to target TRAF6 and
IRAK1 mRNAs. These two genes encode key adaptor
molecules acting downstream of TLRs and cytokine
receptors, suggesting a role for miR-146a in controlling
signaling originated from the activation of these recep-
tors through a negative feedback loop involving downre-
gulation of TRAF6 and IRAK1.
Other studies suggest an important role for miR-146a
in the development of the mechanism of LPS tolerance.
The LPS tolerance is a peculiar property of monocytes
to develop a condition of hyporesponsiveness to LPS
(with reduced TNF-alpha production) upon prolonged
exposure to LPS. This conclusion was based on the
observations that miR-146a continues to increase over
24 h exposure to LPS, while TNF-alpha levels increased
during the first 4 h and then progressively decreased
[18]. Transfection of a miR-146a inhibitor in THP-1
cells inhibited the development of a LPS tolerogenic
response [18]. A role for miR-146a was also shown in
the phenomenon of LPS-induced cross-tolerance, i.e., a
mechanism of tolerance to both homologous and het-
erologous inflammatory ligands [19]. miR-146a could
therefore act as a fine tuning mechanism to prevent an
overstimulation of the inflammatory response.
MiR-146a expression, explored in dendritic cells, is
about 6-fold more highly expressed in Langheran’s cells
than in interstitial dendritic cells generated in vitro from
human granulocyte/myeloid progenitor cells [20].
Importantly, miR-146a expression, at variance with the
findings observed in monocytes, does not increase in
response to cell activation, thus suggesting that in Lan-
gheran’s cells miR-146a expression is constitutively high.
The high expression of miR-146a in Langheran’s cells
seems to be induced by the transcription factor PU.1
[20]. According to these observations it was suggested
that elevated miR-146a expression could be required for
Langheran’s cells development and could prevent in
these cells inappropriate cell activation resulting from
environmental Toll-like receptor ligands.
Role of miR-146a in cell differentiation
Many recent studies indicate that miR-146a expression
is finely tuned during cell differentiation and the miR-
146a-mediated control of some targets plays in turn an
important role in the process of cell differentiation.
Labbaye and Testa Journal of Hematology & Oncology 2012, 5:13
http://www.jhoonline.org/content/5/1/13
Page 3 of 10
These studies were mainly focused to analyze the effect
of miR-146a on hematopoietic cell differentiation.
Some evidences indicate a role for miR-146a in the
control of macrophage differentiation. Ghani et al using
a model of PU.1 inducible cell lines showed that activa-
tion of the expression of this transcription factor
induced a marked upmodulation of miR-146a expression
[21]. Stimulation of miR-146a expression by PU.1 is
mediated by a transcriptional stimulation dependent
upon the binding of PU.1 to a binding motif located at
10 kb upstream of the miR-146a locus. miR-146a was
found to be expressed at low level in purified prepara-
tions of murine common myeloid progenitors and at
markedly higher levels in mature myeloid cells and par-
ticularly in macrophages. Loss of function experiments
in murine and zebrafish models revealed that generation
of the macrophage compartment in embryos requires
the regulatory activity of miR-146a [21]. According to
these findings it was suggested that miR-146a plays an
important role not only in inhibition of pro-inflamma-
tory signaling, but also in promoting macrophage devel-
opment from hematopoietic stem cells [21].
The possible effects of miR-146a deficiency on myelo-
poiesis were evaluated in murine gene knockout models.
Thus Boldin et al reported the knockout (KO) of miR-
146a: as expected, monocytes derived from miR-146a-
null mice were hypersensitive to LPS [22]. Although no
overt abnormalities of hematopoietic differentiation have
been observed in miR-146a-deficient mice, abnormalities
of some hematopoietic lineages were found. Thus miR-
146a-/- mice showed a marked splenomegaly due to the
accumulation and increased proliferation of myeloid ele-
ments CD11b+/Mac1+ [22]. Aging miR-146a KO mice
displayed the development of anemia, thrombocytopenia
and lymphopenia, seemingly in consequence of myelo-
proliferative syndrome [22]. The proliferation of these
myeloid elements seems to be in part due to the overex-
pression of M-CSFR [22]. However, the cellular lineage
of the myeloproliferation and the mechanistic basis of
miR-146a deficiency-mediated myeloproliferation
remained to be evaluated. Thus, in a second study the
same authors showed that miR-146a KO mice developed
myeloid sarcomas through a mechanism mediated via
NF-kB activation induced by miR-146a deficiency [23].
These observations indicate that, in addition to its
anti-inflammatory role, miR-146a plays a negative role
in the development of myeloid elements since its dele-
tion in mice results in a myeloproliferative disorder with
accumulation of CD11b+Mac1+ cells.
In another study a different approach was attempted
to explore miR-146a function in hematopoietic differen-
tiation. Thus, miR-146a was overexpressed in hemato-
poietic stem cells, followed by bone marrow
transplantation. The transplantation of these cells
resulted in a transient myeloid expansion, decreased ery-
thropoiesis and impaired lymphopoiesis [24]. Further-
more, the enforced expression of miR-146a impaired
bone marrow reconstitutuion in recipient mice and
reduced survival of hematopoietic stem cells [24]. It is
also important to note that in this study miR-146a was
found to be expressed mainly in primitive hematopoietic
stem cells, lymphocytes and monocytes [24].
A number of recent studies support a role of miR-
146a in the control of megakaryocytopoiesis. miR-146a
levels have been reported to dramatically change during
megakaryocytic differentiation of hematopoietic progeni-
tor cells, but there is conflicting evidence regarding the
direction of change and the function of miR-146a in
megakaryocytic differentiation. Thus, Labbaye et al
observed that miR-146a is abundantly expressed in
human hematopoietic progenitors cells (HPCs) and its
expression decreased when these cells are induced to
differentiate to megakaryocytes [12]. Importantly, forced
expression of miR-146a into HPCs caused a reduction
of the maturation of megakaryocytic cells, as evidenced
by a reduced expression of membrane megakaryocytic
differentiation markers and a reduction in the number
of polyploidy cells [12]. Conversely, inhibition of miR-
146a expression by antagomir caused an opposite effect,
with increased expression of megakaryocytic differentia-
tion markers and increased polyploidy [12]. The reduc-
tion of miR-146a expression associated with
megakaryocytic differentiation was confirmed also by
Garzon et al [25] who observed miR-146a levels much
higher in normal bone marrow (BM) CD34+ cells than
in BM megakaryocytes [25]. In line with these findings,
Starczynowski et al showed that miR-146a was strongly
downmodulated during hematopoietic differentiation
since it was markedly more expressed in HPCs CD34+
than in CD34- BM precursor cells [26]. In their studies
Starczynowski et al demonstrated that knockdown of
miR-146a and miR-145 in murine HPCs (by overexpres-
sion of decoy targets or anti-miRNA) resulted after
transplant in significant thrombocytosis and increased
megakaryocyte colony formation [26].
In contrast to these findings, Opalinska et al reported
that in murine HPCs induced to differentiate to mega-
karyocytres, the expression of miR-146a increased [27].
Furthermore, these authors showed that overexpression
of miR-146a in mouse bone marrow HPCs produced no
significant alterations in megakaryocyte development in
vivo after transplantation and no changes in megakaryo-
cyte colony assays [27].
The effect of miR-146a overexpression in murine
HPCs was explored also by Starzynowski et al [24].
These authors showed that miR-146a is mainly
expressed in stem/progenitor cells and that its overex-
pression in HPCs, followed by bone marrow
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transplantation, resulted in a number of hematological
abnormalities consisting in transient myeloid expansion,
decreased erythropoiesis and impaired lymphopoiesis;
furthermore, miR-146a overexpression reduced bone
marrow reconstitution capacity [24]. However, surpis-
ingly, miR-146a overexpression did not apparently affect
megakaryocyte number and differentiation [24]. It was
proposed that these apparently conflicting results may
derive from species differences and different experimen-
tal culture conditions that could result in different levels
of functional miR-146a [28]. Particularly, it is possible
that overexpression of miR-146a beyond endogenous
levels could be not sufficient to induce a biological effect
on megakaryocytes [29].
An additional great complexity of these studies is
related to the mechanisms through which miR-146a
could affect megakaryocyte development. Thus, Labbaye
et al provided evidence that miR-146a controls megakar-
yocyte differentiation through a cell autonomous
mechanism related to the targeting of the chemokine
receptor CXCR4. Thus, the decrease of miR-146a
expression observed during megakaryocytic differentia-
tion permits the optimal expression of CXCR4 in devel-
oping megakaryocytes: the autocrine stimulatioin of this
receptor by endogenously released Stromal derived Fca-
tor-1 (SDF-1alpha) activates CXCR4 and its signaling
together with TPOR stimulates megakaryocytic differen-
tiation [12]. In contrast, Starczynovski and coworkers in
their studies on miR-145/miR-146a-deficient mice sug-
gested a different, non cell-autonomous mechanism,
based on the targeting of TRAF6 by miR-146a; TRAF6
acts as a stimulator of IL-6, a cytokine required for opti-
mal megakaryocytic proliferation/differentiation [26].
miR-146a and cancer
Many microRNAs, including miR-146a, have been
shown to contribute to the complex molecular mechan-
isms involved in the control of cell growth, differentia-
tion and survival, processes mainly related to cancer
development and progression (reviewed in 30). A large
number of recent studies has shown the utility of micro-
RNAs as cancer-related biomarkers, as supported by the
finding that some microRNAs display altered expression
profiles in cancers compared to normal tissues [30].
Finally, the altered expression of some of these micro-
RNAs play a key role in tumor progression and there-
fore may represent targets for the development of new
therapies [30].
Many recent studies have suggested a role for miR-
146a in the development and maintenance of neoplastic
processes.
Several studies carried out in papillary thyroid carci-
noma were among the first studies to show abnormal-
ities of miR-146 in some human cancers. Thus, He et al
showed that several miRNAs are up-regulated in papil-
lary thyroid carcinoma compared to normal thyroid tis-
sue: among them, particularly pronounced was the
upregulation of miR-146b, miR-221 and miR-222 [31].
Tumors in which the upregulation of these three miR-
NAs was strong showed a marked loss of kit protein, a
target shared by all three miRNAs [31]. Subsequent stu-
dies provided evidence about a more complex link
between deregulated miR-146 expression and thyroid
papillary cancer development. Thus, Jazdewski et al
showed the existence of a common G/C polymorphism
within the pre-miR-146a sequence, reducing the amount
of miR-146a produced by the involved allele (C allele)
by about 2 fold, compared to the wild-type allele [32].
The reduced production of miR-146a by the C allele
leads to a reduced downmodulation of the correspond-
ing target genes. A screening carried out on a large
number of patients with papillary thyroid carcinoma,
compared to a similarly large number of normal con-
trols showed that the GC heterozygote state, but not the
homozygote CC state, is associated with an increased
risk of acquiring papillary thyroid cancer; furthermore,
4.7% of the tumors had undergone mutations of the
SNP sequence [32].
From this study it remained unclear why heterozigosity
for the G/C polymorphism, but not homozygosity, in the
pre miR-146a predisposes to papillary thyroid cancer. This
point was clarified in a subsequent study showing that GC
heterozygotes, but not GG and CC homozygotes, produce
3 mature microRNAs: one from the leading stand and two
from the passenger strand (miR-146a*G and miR-146a*C),
each with its distinct set of target genes [33]. To under-
stand this point it must be taken into account that miRs
are transcribed from DNA and progressively processed
from primary transcript (pri-miR) to a hairpin precursor
(pre-miR), comprising two strands: the leading strand
used for the production of mature miR and the passenger
strand that is commonly believed to be degraded. There-
fore, the study of miR-146a showed that novel mature
miR is produced from the passenger strand and the pre-
sence of SNP generates two isoforms of the alternative
miR: miR-146a*G from the allele carrying G and miR-
146a*C from the allele carrying C [33]. In a microarray
expression study, the transcriptosomes of individual geno-
types differed considerably, with the modulated genes
mainly involved in the control of apoptosis [34]. This can
determine an exaggerated DNA-damage response in het-
erozygotes, thus explaining the predisposition to develop
thyroid cancer [34].
The increased expression of miR-146a in anaplastic
thyroid cancer could be related to the high and sponta-
neous NF-kB activity observed in these tumor cells: in
fact, it was shown that NF-kB stimulates miR-146a tran-
scription [35].
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Several studies were focused to explore the abnormal-
ities of miR-146 expression in pancreatic carcinoma.
miR-146a expression was found to be downregulated in
pancreatic cells compared to the levels observed in their
normal counterpart [36]. Re-expression of miR-146a in
pancreatic cancer cells led to the inhibition of both
EGFR and NF-kB signaling; this effect is paralleled by a
reduced invasion capacity of these cancer cells [36].
Another study more directly focused to the comparative
analysis of pancreatic tumor tissue and normal pancrea-
tic tissue: thus, pancreatic intraepithelial neoplasms and
pancreatic ductal adenocarcinomas differentially
expressed 35 miRNAs compared with normal pancreatic
ductal tissue and, among them, one of the most down-
modulated was miR-146a [37]. A rescue of miR-146a
expression in pancreatic cancer cells could contribute to
the inhibition of the malignant phenotype. Thus, Bao et
al have shown that curcumin inhibits pancreatic tumor
growth by attenuating the expression of the histone
methyl-transferase E2H2 and increasing the expression
of a panel of tumor suppressor miRNA, including miR-
146a [38].
miR-146a levels have been explored in a large set of
gastric cancer patients and resulted to be significantly
lower in cancerous than in noncancerous tissue [9].
Furthermore, the subdivision of these 90 gastric cancer
patients into two subgroups, i.e., those exhibiting high
and those exhibiting low miR-146a levels, showed that
the low-expression miR-146a group exhibited more
extensive lymph node metastasis and venous invasion
than the high-expression group and, importantly, a sig-
nificantly poorer prognosis, as evaluated in terms of
median survival time [9]. These findings were confirmed
by Hou and coworkers who showed decreased miR-146a
expression in 84% of cases and association of low miR-
146a expression with reduced overall survival [39]. The
link between miR-146a and gastric cancer is also related
to the possible effects of this miRNA on the inflamma-
tory response of Helicobacter pylori, a major human
pathogenic bacterium in gastric mucosa. Particularly,
Helicobacter pylori induces miR-146a expression
through a NF-kB-dependent mechanism: in turn, miR-
146a downregulates the expression of target genes,
including IRAK1, TRAF6, IL-8 and, through this
mechanism, modulates the inflammatory response
[40,41].
miR-146a expression was studies in breast cancer.
Constitutive NF-kB activity was frequently observed in
breast cancer and was associated with aggressive breast
cancer clinical behavior. Using the highly metastatic
breast cancer cell line MDA-MB-231, exhibiting spon-
taneous NF-kB activation, Bhaumik et al showed that
enforced miR-146a expression inhibited endogenous
NFkB expression/activity and reduced the metastatic
potential of these tumor cells [42]. A second study
showed that the breast cancer metastasis suppressor 1
(BRMS1) could act by upmodulating miR-146a levels
[7]. BRMS1 is a metastasis suppressor that affects mul-
tiple steps in the metastasis cascade of breast carci-
noma, acting through different mechanisms which
involve various genes whose function is related to the
control of the metastatic potential. Thus, it was shown
that BSMS1 markedly activates both miR-146a and
miR-146b expression in breast carcinoma cells and,
through this mechanism, inhibits EGFR expression,
thus leading to a reduced metastatic potential of these
cells [7].
Other studies suggest a possible role for miR-146a in
prostate cancer. Lin et al performed a screening of miRs
exhibiting a differential expression in androgen-indepen-
dent as compared to androgen-dependent prostate can-
cer cell lines. Among the 8 miRNAs downregulated in
androgen-resistant cell lines, compared to androgen-
dependent cell lines, there were miR-146a and miR-
146b [10]. In situ hybridization analysis of miR-146a
expression in tissue prostate cancer sections showed
that this miR is highly expressed in normal prostate tis-
sue and significantly downmodulated in prostate cancer
tissue [10]. Transfection of miR-146a in an androgen-
independent prostate cancer cell line resulted in a
marked reduction of cell proliferation, invasion and
metastasis to bone marrow, an effect seemingly
mediated by the targeting of ROCK1, one of the key
kinases for the activation of hyaluronan [10].
Recent studies indicate that a deregulated miR-146a
expression could contribute to glioma development
through the targeting of NOTCH1, a cell signaling path-
way playing a key role in the mechanism of neural stem
cell development and maintenance in the adult life. Par-
ticularly, studies carried out in human glioblastomas
have shown that miR-146a expression is upregulated in
the tumor tissue, compared to the normal neural tissue
[43]. In spite this enhanced expression in glioblastomas,
experiments carried out in models of experimental glio-
magenesis have shown that EGFR stimulation and
PTEN inactivation induces miR-146a expression, that in
turn acts as a mechanism limiting glioma development,
through NOTCH1 targeting [11]. In particular, miR-
146a plays an inhibitory role by restricting the formation
of glioma stem-like cells and reducing the proliferation
of glioma cells [11]. These observations suggest that
miR-146a constitutes an endogenous feedback mechan-
ism to counteract the oncogenic potential of dysregu-
lated signaling pathways [11].
A G > C polymorphism in the miR-146a precursor
sequence was shown to be positively associated with risk
of developing glioma and with clinical prognosis in adult
glioma patients [44].
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Wang and coworkers have explored the pattern of
miRNAs expression in cervical cancer, compared with
normal cervical tissue. Several miRNAs appeared to be
deregulated in their expression and, among them,
miRNA-146a was found to be 10 fold upmodulated in
cancer tissue compared to normal cervical tissue [45].
Surprisingly, cervical carcinoma cell lines were found to
express miR-146a at very low levels and enforced
expression of miR-146a in these cells caused a stimula-
tory effect on cell proliferation [45].
Recent studies on mouse miR-146a knockout models
strongly supports a role for miR-146a as a tumor sup-
pressor for myelo-lymphoid cells. In fact, the loss of
miR-146a favors the development of myeloid and lym-
phoid neoplasia [22,23]. miR-146a KO mice developed
at the age of 5-6 months a massive myeloproliferative
disease. In fact, these mice showed a markedly enlarged
spleen, massively infiltrated with myeloid blast precur-
sors CD11b+GR1+ cells [22]. Concomitantly, these mice
displayed anemia, thrombocytopenia and lymphopenia,
as well as extramedullary erythropoiesis [22]. A mild
and variable expansion of CD11b+ cells was observed
also in the BM of miR-146a KO mice [22]. The myelo-
proliferation induced by miR-146a loss seems to be
related to a deregulated activation of NF-kB [23] and
the hyperexpression of M-CSFR in myeloid elements
[22]. At later times in these KO animals often the mye-
loproliferation of spleen progresses up to the formation
of splenic sarcomas and lymphomas of either B or T
lineage are observed in older KO mice at a much higher
frequency than in the normal WT animals [23].
A possible deregulation of miR-146 has been explored
in various leukemic processes. Visone et al have
explored the karyotype-specific miRNA signature in
chronic lymphocytic leukemia (CLL) and found 9 miR-
NAs, including miR-146a and miR-146b, whose expres-
sion is deregulated in CLL compared to their normal
counterpart [46]. The expression level of these miRs was
correlated with gene expression data [46].
Several studies were devoted to the analysis of miR-
146 expression in the various subtypes of acute myeloid
leukemia (AML). Garzon et al performed a large screen-
ing on miRNA expression in 122 untreated AML sam-
ples, compared to normal CD34+ cells [47]. miR-146a
was among the miRs whose expression was most down-
modulated, compared to normal CD34+ cells [47].
Lutherborrow et al have compared the expression of
some miRNAs, including miR-146a and miR-146b, in
FAB M1 and FAB M5 AMLs [48]. In FAB M5 AMLs
the expression of both miR-146a and miR-146b was
lower than in FAB M1 AMLs; furthermore, miR-146a
expression was significantly downmodulated during
monocytic differentiation of AML cell lines induced by
chemical inducers [48].
Spinello et al reported a detailed analysis of miR-146a
expression in 38 untreated AML samples and observed
heterogeneous levels for each FAB subtype, with the
mean lowest levels observed in FAB M5 AML samples;
furthermore, in many AML samples mR-146a levels
were significantly lower than those observed in normal
CD34+ cells [49]. In parallel, it was investigated the level
of one of the miR-146a targets, i.e., CXCR4: thus,
CXCR4 protein levels were found to be inversely related
to the levels of miR-146a, the highest CXCR4 levels
being observed among FAB M5 AMLs [49]. Induction
of differentiation of leukemic monocytic cell lines, such
as U937, using a chemical inducer such as 1alpha25OH-
VitD3, determines an upmodulation of miR-146a
expression, accompanied by a concomitant reduction of
CXCR4 protein levels. Importantly, enforced expression
of miR-146a in leukemic cell lines determines a reduced
cell proliferation and an increased sensitivity to the
cytotoxic effects of anti-leukemic drugs [49].
Starczynowski et al have explored miR-146a expres-
sion in CD34+ cells derived from 54 primary AML sam-
ples of patients with normal karyotype and observed
reduced levels in leukemic samples compared to their
normal counterpart [50]. Experiments carried out in leu-
kemic cell lines, such as HL60, and showing an
increased miR-146a expression following treatment with
demethylating agents suggests that epigenetic mechan-
isms could be responsible for the reduced expression of
miR-146a observed in these AML samples [50].
Enforced expression of miR-146a in these leukemic cell
lines resulted in a clear inhibitory effect on cell prolif-
eration [50].
Using the promyelocytic leukemia NB4 cell line,
Zhang et al observed a downmodulation of miR-146a
during ATRA (All Trans Retinoic Acid)-induced granu-
locytic differentiation, associated with upregulation of
Smad4 protein levels [50]. According to these findings it
was suggested that a role for the miR-146a/Smad4 regu-
latory pathway in retinoic acid-induced differentiation of
APL cells [51].
In some myelodysplastic syndromes a genetic mechan-
ism is directly responsible for the low expression of
miR-146a. In fact, in the myelodysplastic 5q- syndrome,
the deletion of chromosome 5q correlates with the loss
of two miRNAs, miR-145 and miR-146a [26]. Functional
experiments have shown that the loss of these two miRs
is responsible for main features of the 5q- syndrome,
such as neutropenia and thrombocytosis [26]. Other stu-
dies have confirmed decreased miR-146a levels in CD34
+ cells of the 5q- myelodysplastic syndrome compared to
the levels observed in normal CD34+ cells [52]. How-
ever, surprisingly, normal miR-145 levels have been
observed in CD34+ 5q- MDS cells [52]. Particularly,
although four miRNAs (miR-143, miR-145, miR-146a
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and miR-378) were mapped within the 5q deletion, only
two of them, miR-146a and miR-378 showed reduced
expression in 5q- patients [52]. The non reduced miR-
145 levels observed in CD34+ cells could be explained
by the recent finding that p53 transcriptionally induces
miR-145 by interacting with a p53 response element
present in the miR-145 promoter [53]. In fact, following
the del (5q) one allele of miR-145 is lost, while the
remaining allele could be transcriptionally hyperactive in
consequence of p53-mediated stimulation.
An important issue in the analysis of the effects of
miR-145 and miR-146 loss on the development of the
myelodysplastic syndrome consisted in the study of irra-
diated mice transplanted with mouse stem/progenitor
cells stably knocked down for miR-145 and miR-146
expression by retroviral-mediated overexpression of
miR-145 and miR-146 target sequences (miR decoy).
These mice initially developed a myelodysplastic syn-
drome, followed at distance of several months by the
development of an acute myeloid leukemia [47].
However, the exact role and the contribution of miR-
145 and miR-146 loss in 5q- syndrome need to be care-
fully assessed in future studies [54].
MiR-146a expression was explored in chronic myeloid
leukemia (CML) and, particularly, the changes in its
expression occurring after treatment with imatinib. In
untreated CML cells miR-146a levels were found to be
significantly decreased compared to appropriate normal
controls [55]. Interestingly, following treatment with
imatinib miR-146a levels, as well as miR-150 levels, pro-
gressively increased up to restore normal levels of
expression after 14 days of treatment with the tyrosine
kinase inhibitor [55]. According to these findings it was
suggested that the decreased miR-146a expression
observed in untreated CML cells could contribute to
mediate the BCR/ABL-induced NFkB constitutive acti-
vation; on the other hand, the increased miR-146a
expression observed following imatinib treatment, could
contribute to mediate the imatinib-induced NFkB inhi-
bition [55].
A number of recent studies has shown a deregulation
of miR-146a expression in some peculiar types of lym-
phomas. Among them particularly interesting are the
observations made about miR-146a in NK/T cell lym-
phomas. The study carried out in this lymphoma has
lead to the conclusion that miR-146a down-regulates
NFkB activity via targeting TRAF6 and functions as a
tumor suppressor having strong prognostic implications
in NKT lymphomas [56]. This conclusion was based on
the basic observation that NKT cell lymphomas with
low miR-146a expression have a poor prognosis com-
pared to those with high miR-146a expression [56].
Furthermore, in vitro miR-146a overexpression in NKT
cell lines inhibited proliferation, induced apoptosis, and
enhanced chemosensitivity [56].
MiR-146 expression is deregulated in virus-induced
lymphoid neoplasias. Human T lymphotropic virus type
I (HTLV1) is the etiologic agent of a severe and fatal
lymphoproliferative disease, mainly affecting CD4+ T
lymphoid cells, adult T acute leukemia. Pichler et al
have explored the miRNA profile of expression in
HTLV1-transformed cells and observed that several
miRs, including miR-21, miR-146a and miR-155 are
hyper-expressed in HTLV1-transformed cells [57]. The
mechanisms of miR-146a upregulation seem to be
related to a stimulatory effect exerted by Tax, via NF-
kB-mediated transactivation through binding to a NF-kB
response element present in the miR-146a promoter
[57]. In a second study Tomita and coworkers modu-
lated miR-146a levels in HTLV1-transformed cells and
observed that miR-146a inhibition in these cells by a
specific antagomir elicited an inhibitory effect on cell
growth, and opposite effect was induced by miR-146a-
enforced expression [58].
The Epstein-Barr virus (EBV) infection is associated
with the development of some lymphoid and epithelial
cancers. EBV infection gives rise to an initial alteration
of lymphocyte gene expression, which determines a sti-
mulation of cellular proliferation and changes in the dif-
ferentiation program, in consequence of the transition
of the virus through consecutive latency transcription
programs. The EBV-induced proliferation program
involves pronounced changes at the level of various
miRNAs, including miR-146a [59,60]. In this context,
two initial studies have shown that the EBV-encoded
latent membrane protein 1 induces the expression of
miR-146a via NF-kB [59,60]. It was suggested that the
induction of miR-146a may play a role in the induction
or in the maintenance of EBV latency through the mod-
ulation of innate immune responses to the virus-infected
host cells. A more recent study showed that de novo
infection of primary human B lymphocytes with EBV
induced a transient initial miR-146a downmodulation,
followed by a pronounced upregulation more than 100
fold upon induction of the viral lytic cycle: this strong
miR-146a induction seems to have inhibitory effects on
the progression of the virus lytic cycle [60].
Conclusion and future perspectives
The discovery of miRNAs as important regulators of
gene expression shed a new light on our understanding
of many biological processes. From the studies carried
out during these last years it became evident miR-146a
plays a key role as a modulator of the innate immune
response. However, recent studies indicate also an
important role of this miRNA in the control of normal
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hematopoiesis, particularly for that concerns the mega-
karyocytic and monocytic lineages. However, the
mechanism, either direct or indirect through which
miR-146a affects megakaryocytopoiesis and monocyto-
poiesis is still debated and additional studies are
required to solve this issue.
On the other hand, growing evidence indicates a
deregulation of miR-146a in many neoplastic conditions.
This is the case of 5q- syndrome associated to myelodys-
plasia, where a deficiency of miR-146a is observed. The
deficiency of miR-146a, together with deficiency of miR-
145, seems to be responsible for abnormalities of throm-
bopoiesis observed in this disease. Although the
mechanism through which miR-146a induces a dysme-
gakaryopoiesis in 5q- syndrome remains still unclear,
knockout studies of the miR-146a locus indicate that
reduced miR-146a expression affects hematopoiesis and
contributes to features of myelodysplasia and leukemia.
In line with these indications miR-146a expression is
clearly downmodulated in many AMLs may contribute
to the malign phenotype. Furthermore, miR-146a
expression is deregulated in many solid tumors and
there is consistent evidence that miR-146a may act as a
tumor suppressor. However, the mechanism through
which a miR-146a downmodulation may favor tumor
development and/or maintenance is at the moment
unclear, but it seems related to the capacity of this
miRNA to target some mRNAs, such as TRAF6, IRAK1,
CXCR4, EGFR. Future studies will unveil the molecular
mechanisms through which miR-146a contributes to
tumor development.
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